• KOL
    • Irritable Bowel Syndrome
    • Douglas A Drossman
    • Douglas A Drossman: Influence Statistics

      Douglas A Drossman

      Douglas A Drossman

      Show email address

      Rome Foundation, Raleigh, NC, USA | UNC Center for Functional GI and Motility Disorders, Durham, NC, USA | Center for Functional GI and Motility Disorders, University of North ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Douglas A Drossman:Expert Impact

      Concepts for whichDouglas A Drossmanhas direct influence:Irritable bowel syndrome,Bowel syndrome,Irritable bowel,Abdominal pain,Psychosocial factors,Medical schools,Narcotic bowel syndrome,Gastrointestinal illness.

      Douglas A Drossman:KOL impact

      Concepts related to the work of other authors for whichfor which Douglas A Drossman has influence:Irritable bowel syndrome,Abdominal pain,Functional dyspepsia,Inflammatory bowel disease,Ibs patients,Chronic constipation,Quality life.

      KOL Resume for Douglas A Drossman

      Year
      2021

      Rome Foundation, Raleigh, NC, USA

      Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Center for Education and Practice of Biopsychosocial Care, Drossman Gastroenterology, Chapel Hill, North Carolina.

      2020

      Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, Chapel Hill, NC, USA

      2019

      Center for Education and Practice of Biopsychosocial Care, Center for Functional GI and Motility Disorders, University of North Carolina, Drossman Gastroenterology, Chapel Hill NC, and the Rome Foundation, Raleigh NC, USA

      2018

      Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, and Center for Education and Practice of Biopsychosocial Care and Drossman Gastroenterology, Chapel Hill, North Carolina

      2017

      UNC Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, 55 Vilcom Center Drive, Suite 110, 27514, Chapel Hill, NC, USA

      From the Department of Internal Medicine, Division of Gastroenterology (Aroniadis), Montefiore Medical Center-Albert Einstein College of Medicine, Bronx, New York; Center for Functional Gastrointestinal and Motility Disorders (Drossman, Simrén), University of North Carolina at Chapel Hill, North Carolina; Drossman Gastroenterology (Drossman, Simrén), Chapel Hill, North Carolina; and Department of Internal Medicine and Clinical Nutrition (Simrén), Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden.

      Center for Functional Gastrointestinal and Motility Disorders, University of North Carolina, Chapel Hill, NC.

      Department of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, NC

      2016

      Center for Education and Practice of Biopsychosocial Care, Drossman Gastroenterology, Chapel Hill, NC, USA

      Rome Foundation, Chapel Hill, North Carolina

      2015

      University of North Carolina at Chapel Hill Drossman Center for the Education and Practice of Biopsychosocial Care Professor Emeritus of Medicine and Psychiatry UNC Center for Functional GI and Motility Disorders Chapel Hill NC USA

      2014

      Professor Emeritus of Medicine and Psychiatry, Center for Functional GI and Motility Disorders, University of North Carolina, President, Center for Education and Practice of Biopsychosocial Care and Drossman Gastroenterology PLLC, Chapel Hill, NC.

      UNC Center for Functional GI and Motility Disorders Drossman Gastroenterology PLLC Chapel Hill NC USA

      University of North Carolina and Drossman Gastroenterology PLLC, Chapel Hill

      2013

      The Drossman Center for the Education & Practice of Biopsychosocial Care, LLC, Chapel Hill, North Carolina

      Drossman Center for the Education and Practice of Biopsychosocial Care LLC, and UNC Center for Functional GI and Motility Disorders, Chapel Hill, NC, USA

      2012

      Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

      Department of Medicine, Clinical Sciences Building, Cork University Hospital, Cork, Ireland

      2011

      Codirector, Center for Functional GI and Motility Disorders Professor of Medicine and Psychiatry School of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina.

      UNC Center for Functional GI and Motility Disorders, Chapel Hill, North Carolina, USA

      Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina

      2010

      UNC Center for Functional GI and Motility Disorders, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Douglas A Drossman is among the top experts in the world.
      Concept World rank
      ibsar baseline severity #1
      abuse measure paper #1
      sexual physical abuse #1
      linear causative fashion #1
      structural disease studies #1
      specific cultural contributions #1
      form pprs #1
      anticipated difficulty patients #1
      disease symptoms depression #1
      antibody reactivity autoantigens #1
      studies symptom criteria #1
      openlabel lubiprostone #1
      clinical trials fgid #1
      patients opioidsthe mechanisms #1
      gerson respect #1
      work gerson #1
      entities epidemiological data #1
      faps health impact #1
      safety lubiprostone doses #1
      factors illness condition #1
      flare increased disability #1
      narcotic bowel #1
      role psychotropic agents #1
      oic clinical #1
      health pretending #1
      ibsc ibsd #1
      health behavior dysfunction #1
      ∼5 patients #1
      documents journal issue #1
      physicians perceptions patients #1
      endoscopic sphincter ablation #1
      p0001 data #1
      conclusions respects #1
      522 ibsc patients #1
      foster international networks #1
      prevalence bowel dysfunction #1
      caps result #1
      sexual 53 #1
      gastrointestinal disorders model #1
      gutbrain interaction #1
      major trauma abuse #1
      ercp interventions manometry #1
      documents description #1
      central neuromodulators treatments #1
      ibs psychosocial #1
      32 16 microg #1
      functional illnesses #1
      opportunities enhanced physician #1
      production documents #1
      sexual abuse comparison #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Douglas A Drossman

      KOL-Index: 17199

      IMPORTANCE: Abdominal pain after cholecystectomy is common and may be attributed to sphincter of Oddi dysfunction. Management often involves endoscopic retrograde cholangiopancreatography (ERCP) with manometry and sphincterotomy.

      OBJECTIVE: To determine whether endoscopic sphincterotomy reduces pain and whether sphincter manometric pressure is predictive of pain relief.

      DESIGN, SETTING, AND PATIENTS: Multicenter, sham-controlled, randomized trial involving 214 patients with pain after ...

      Known for Endoscopic Sphincterotomy | Suspected Sphincter | Ercp Patients | Abdominal Pain | Oddi Dysfunction
      KOL-Index: 16502

      BACKGROUND: The implications of the Rome III recommendations to change the irritable bowel syndrome (IBS) subtype criteria for stool pattern are unknown.

      AIM: (1) Determine the level of agreement between Rome II and Rome III subtypes and (2) compare the behaviors of Rome II and Rome III subtypes over time.

      METHODS: Female patients (n=148) with Rome II defined IBS were prospectively tracked over 5 consecutive 3-month periods. At baseline, bowel habit reports on questionnaires were used to ...

      Known for Rome Iii | Irritable Bowel | Illness Surveys Questionnaires | Subtypes Time | Ibs Subtype
      KOL-Index: 12478

      OBJECTIVES: Using interview data from a large, community-based sample of American women, we assessed the lifetime prevalence of irritable bowel syndrome (IBS) using questions consistent with the Rome II criteria, determined the sensitivity of Rome I and II in women diagnosed with IBS by their community physician, and identified whether there are differences in the patients identified by Rome I versus II.

      METHODS: A geographically diverse national probability sample of women diagnosed ...

      Known for Ibs Rome | Irritable Bowel | Specificity Surveys | Community Sample | Screening Interviews
      KOL-Index: 11886

      OBJECTIVES: Irritable bowel syndrome (IBS) patients show pain hypersensitivity and hypercontractility in response to colonic or rectal distention. Aims were to determine whether predominant bowel habits and IBS symptom severity are related to pain sensitivity, colon motility, or smooth muscle tone.

      METHODS: One hundred twenty-nine patients classified as IBS with diarrhea (IBS-D, N = 44), IBS with constipation (IBS-C, N = 29), mixed IBS (IBS-M, N = 45), and unspecified IBS (IBS-U, N = 11) ...

      Known for Pain Sensitivity | Ibs Symptom Severity | Colonic Motility | Bowel Habit | Illness Surveys
      KOL-Index: 11516

      PURPOSE: This study aimed to compare manometric biofeedback with pelvic floor exercises for the treatment of fecal incontinence in a randomized controlled trial controlling for nonspecific treatment effects.

      METHODS: After excluding patients who were adequately treated with medication, education, and behavioral strategies (21%), 108 patients (83 females; average age, 59.6 years) underwent either pelvic floor exercises alone (n = 63) or manometric biofeedback plus pelvic floor exercises ...

      Known for Fecal Incontinence | Pelvic Floor | Randomized Controlled Trial | Biofeedback Patients | Life Illness
      KOL-Index: 11435

      BACKGROUND & AIMS: Studies of antidepressants and psychological treatments in functional bowel disorders (FBD) are methodologically limited. The aim of this study was to assess the clinical efficacy and safety of cognitive-behavioral therapy (CBT) against education (EDU) and desipramine (DES) against placebo (PLA) in female patients with moderate to severe FBD (irritable bowel syndrome, functional abdominal pain, painful constipation, and unspecified FBD). We also evaluated the ...

      Known for Behavioral Therapy | Functional Bowel Disorders | Versus Placebo | Diarrhea Female Humans | Pla Fbd
      KOL-Index: 11372

      OBJECTIVE: To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude of these components.

      DESIGN: A six week single blind three arm randomised controlled ...

      Known for Irritable Bowel Syndrome | Controlled Trial | Quality Life | Adequate Relief | Waiting List
      KOL-Index: 11270

      Patient education improves clinical outcomes in patients with chronic illness, but little is known about the education needs of patients with IBS.

      OBJECTIVES: The objective of this study was to identify: (1) patients perceptions about IBS; (2) the content areas where patients feel insufficiently informed, i.e., "knowledge gaps" about diagnosis, treatment options, etiology, triggers, prognosis, and role of stress; and (3) whether there are differences related to items 1 and 2 among ...

      Known for Patient Education | National Survey | Irritable Bowel | Chronic Illness | Syndrome Ibs
      KOL-Index: 11268

      BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is subtyped as IBS with diarrhea (IBS-D) or IBS with constipation (IBS-C) based on Rome II guidelines. The remaining group is considered as having mixed IBS (IBS-M). There is no standard definition of an alternator (IBS-A), in which bowel habit changes over time. Our aim was to use Rome II criteria to prospectively assess change in bowel habit for more than 1 year to understand IBS-A.

      METHODS: Female patients (n=317) with IBS entering a ...

      Known for Bowel Habit | Ibsd Ibsc | Prospective Assessment | Rome Criteria | 1 Year
      KOL-Index: 10930

      This article reviews the evidence for validity of symptom-based criteria (Manning, Rome I, Rome II, and Rome III) for irritable bowel syndrome (IBS). Two kinds of validations are reported: (i) studies testing whether symptom criteria discriminate patients with structural disease at colonoscopy from patients without structural disease; and (ii) studies testing whether symptom criteria discriminate patients presumed to have IBS by positive diagnosis from healthy subjects or patients with ...

      Known for Irritable Bowel Syndrome | Rome Criteria | Sensitivity Specificity | Symptoms Ibs | Symptom Based
      KOL-Index: 10897

      AimsThe aim of this study is to assess the efficacy and safety of lubiprostone in adults with chronic constipation.MethodsThis multicenter, parallel-group trial enrolled 237 patients with chronic constipation and randomized them to 4 weeks of double-blind treatment with oral lubiprostone 24 mcg or placebo twice daily. The primary efficacy endpoint was the number of spontaneous bowel movements (SBMs) after 1 week of treatment. Secondary evaluations included SBMs at weeks 2, 3, and 4; ...

      Known for Chronic Constipation | Lubiprostone Patients | Sbms Week | Efficacy Safety | Abdominal Bloating
      KOL-Index: 10880

      BACKGROUND: No currently available treatment provides consistent relief of irritable bowel syndrome. Colonic sensory and motor function are modulated partly through 5HT3-receptors.

      AIM: To evaluate effects of the 5HT3-receptor antagonist, alosetron, in irritable bowel syndrome.

      METHODS: Randomized, double-blind, placebo-controlled, dose-ranging (1, 2, 4, 8 mg b.d. alosetron), 12-week trial in 370 patients with diarrhoea-predominant or alternating constipation and diarrhoea irritable ...

      Known for Bowel Function | Adequate Relief | 5‐ht3 Receptor Antagonist | Stool Consistency | Alosetron Treatment
      KOL-Index: 10843

      BACKGROUND: Analyses of a trial in constipated patients indicated that lubiprostone may be an effective treatment for irritable bowel syndrome with constipation.

      AIM: To assess the efficacy and safety of three lubiprostone doses for irritable bowel syndrome with constipation.

      METHODS: 195 irritable bowel syndrome with constipation patients received daily doses of 16 [8 microg twice daily (b.d.)], 32 (16 microg b.d.) or 48 microg (24 microg b.d.) lubiprostone or placebo b.d. for 3 months. ...

      Known for Irritable Bowel Syndrome | Lubiprostone Treatment | Clinical Trial | Constipation Patients | Efficacy Safety
      KOL-Index: 10741

      AIMS: To compare quality of life (QOL) for patients with irritable bowel syndrome (IBS) between the U.S. and Japan, it is indispensable to develop common instruments. The IBS-QOL, which is widely used in Western countries, was translated into Japanese as there has been a lack of Japanese disease-specific QOL measures for IBS.

      METHODS: The original 34 items of the IBS-QOL were translated from English into Japanese through two independent forward translations, resolution, back translation, ...

      Known for Ibs Qol | Japanese Version | Irritable Bowel | Rome Criteria | Internal Consistency

      Key People For Irritable Bowel Syndrome

      Top KOLs in the world
      #1
      Douglas A Drossman
      irritable bowel syndrome abdominal pain psychosocial factors
      #2
      Nicholas Joseph Talley
      functional dyspepsia irritable bowel syndrome emergency action
      #3
      William E Whitehead
      irritable bowel syndrome fecal incontinence abdominal pain
      #4
      Emeran A Mayer
      irritable bowel syndrome ibs patients food addiction
      #5
      Peter James Whorwell
      irritable bowel syndrome rectal sensitivity ulcerative colitis
      #6
      Robin Charles Spiller
      irritable bowel syndrome diverticular disease magnetic resonance

      Rome Foundation, Raleigh, NC, USA | UNC Center for Functional GI and Motility Disorders, Durham, NC, USA | Center for Functional GI and Motility Disorders, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Center for Education

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.